Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity

Annals of Applied Statistics

Volumn 7, Issue 4, 2013, Pages 2138-2156

  Liu, Suyu ^a   Yin, Guosheng ^b   Yuan, Ying ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bayesian adaptive design; Late onset toxicity; Nonignorable missing data; Phase I clinical trial

Indexed keywords

EID: 84891532608     PISSN: 19326157     EISSN: 19417330     Source Type: Journal    
DOI: 10.1214/13-AOAS661     Document Type: Article

References (26)

1. Braun, T. M. (2006). Generalizing the TITE-CRM to adapt for early-and late-onset toxicities. Stat. Med. 25 2071-2083. MR2239633.
2. Cheung, Y. K. and Chappell, R. (2000). Sequential designs for phase I clinical trials with lateonset toxicities. Biometrics 56 1177-1182. MR1815616.
3. Coia, L. R., Myerson, R. and Tepper, J. E. (1995). Late effects of radiation therapy on the gastrointestinal tract. International Journal of Radiation Oncology, Biology, Physics 31 1213-1236.
4. Daimon, T., Zohar, S. and O'Quigley, J. (2011). Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method. Stat. Med. 30 1563-1573. MR2828889.
5. Daniels, M. J. and Hogan, J. W. (2008). Missing Data in Longitudinal Studies: Strategies for Bayesian Modeling and Sensitivity Analysis. Monographs on Statistics and Applied Probability 109. Chapman & Hall/CRC, Boca Raton, FL. MR2459796.
6. Desai, S. P., Ben-Josef, E., Normolle, D. P., Francis, I. R., Greenson, J. K., Simeone, D. M., Chang, A. E., Colletti, L. M., Lawrence, T. S. and Zalupski, M. M. (2007). Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J. Clin. Oncol. 25 4587-4592.
7. Garrett-Mayer, E. (2006). The continual reassessment method for dose-finding studies: A tutorial. Clin. Trials 3 57-71.
8. Goodman, S. N., Zahurak, M. L. and Piantadosi, S. (1995). Some practical improvements in the continual reassessment method for phase I studies. Stat. Med. 14 1149-1161.
9. Heyd, J. M. and Carlin, P. B. (1999). Adaptive design improvements in the continual reassessment method for phase I studies. Stat. Med. 18 1307-1321.
10. Iasonos, A. and O'Quigley, J. (2011). Continual reassessment and related designs in dosefinding studies. Stat. Med. 30 2057-2061. MR2829155.
11. Lee, S. M. and Cheung, Y. K. (2011). Calibration of prior variance in the Bayesian continual reassessment method. Stat. Med. 30 2081-2089. MR2829158.
12. Leung, D. H. Y. and Wang, Y. G. (2002). An extension of the continual reassessment method using decision theory. Stat. Med. 21 51-63.
13. Little, R. J. A. and Rubin, D. B. (2002). Statistical Analysis with Missing Data, 2nd ed. Wiley, Hoboken, NJ. MR1925014.
14. Liu, S., Yin, G. and Yuan, Y. (2013). Supplement to "Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. " DOI:10.1214/13-AOAS661SUPP.
15. Mauguen, A., Le Deley, M. C. and Zohar, S. (2011). Dose-finding approach for dose escalation with overdose control considering incomplete observations. Stat. Med. 30 1584-1594. MR2828891.
16. Möller, S. (1995). An extension of the continual reassessment methods using a preliminary upand-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat. Med. 14 911-922.
17. Muler, J. H., McGinn, C. J., Normolle, D., Lawrence, T., Brown, D., Hejna, G. and Zalupski, M. M. (2004). Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J. Clin. Oncol. 22 238-243.
18. O'Quigley, J. and Paoletti, X. (2003). Continual reassessment method for ordered groups. Biometrics 59 430-440. MR1987410.
19. O'Quigley, J., Pepe, M. and Fisher, L. (1990). Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 46 33-48. MR1059105.
20. Postel-Vinay, S., Gomez-Roca, C., Molife, L. R., Anghan, B., Levy, A., Judson, I., Bono, J. D., Soria, J., Kaye, S. and Paoletti, X. (2011). Phase I trials of molecularly targeted agents: Should we pay more attention to late toxicities? J. Clin. Oncol. 29 1728-1735.
21. Shen, L. Z. andO'Quigley, J. (1996). Consistency of continual reassessmentmethod undermodel misspecification. Biometrika 83 395-405. MR1439791.
22. Tanner, M. A. andWong, W. H. (1987). The calculation of posterior distributions by data augmentation. J. Amer. Statist. Assoc. 82 528-550. MR0898357.
23. Wages, N. A., Conaway, M. R. and O'Quigley, J. (2011). Continual reassessment method for partial ordering. Biometrics 67 1555-1563. MR2872406.
24. Wages, N. A., Conaway, M. R. and O'Quigley, J. (2013). Using the time-to-event continual reassessment method in the presence of partial orders. Stat. Med. 32 131-141. MR3017889.
25. Yin, G. and Yuan, Y. (2009). Bayesian model averaging continual reassessment method in phase I clinical trials. J. Amer. Statist. Assoc. 104 954-968. MR2750228.
26. Yuan, Y. andYin, G. (2011). Robust EMcontinual reassessment method in oncology dose finding. J. Amer. Statist. Assoc. 104 818-831. MR2894740.